A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer

Conditions

Tarlatamab — DRUG
Tarlatamab will be administered as an intravenous (IV) infusion.

To evaluate the safety and tolerability of Tarlatamab and will determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D).

Experimental: Part 1: Dose Exploration
The maximum tolerated dose (MTD) will be estimated using isotonic regression (Ji et al, 2010). The recommended phase 2 dose (RP2D) may be identified based on emerging safety data prior to reaching an MTD.
Experimental: Part 2: Dose Expansion
Participants will receive the RP2D/MTD identified in Part 1 (dose exploration) of the study.

Number of Participants Who Experienced One or More Treatment-emergent Adverse Events (TEAEs) [ Time Frame: Up to approximately 3 years ]

Facility	City	State	ZIP	Site coordinators
Mayo Clinic Arizona	Phoenix	Arizona	85054	-
University of California at San Francisco Helen Diller Family Comprehensive Cancer Center	San Francisco	California	94158	-
Winship Cancer Institute of Emory University	Atlanta	Georgia	30322	-
University of Chicago	Chicago	Illinois	60637	-
Community Health Network MD Anderson Cancer Center - North	Indianapolis	Indiana	46250	-
Washington University	St Louis	Missouri	63110-1093	-
Weill Cornell Medical College	New York	New York	10021	-
Wake Forest University Health Sciences	Winston-Salem	North Carolina	27103	-
The Ohio State University	Columbus	Ohio	43210	-
University of Texas MD Anderson Cancer Center	Houston	Texas	77030	-

By research site